Familial Adenomatous Polyposis Market Report 2030
Familial Adenomatous Polyposis (FAP) is a genetic condition. It is diagnosed when a person develops more than 100 adenomatous colon polyps. An adenomatous polyp is an area where normal cells that line the inside of a person’s colon form a mass on the inside of the intestinal tract. On an average, polyps develop in people with FAP is in the mid-teens. Most people with FAP will have multiple colon polyps by age 35. If FAP is not recognized and treated, there is a very high likelihood that a person will develop colorectal cancer.
DelveInsight’s “ Familial Adenomatous Polyposis — Market Insights, Epidemiology, and Market Forecast-2030 “ report delivers an in-depth understanding of the Familial Adenomatous Polyposis, historical and forecasted epidemiology as well as the Familial Adenomatous Polyposis market trends in the United States, EU5 ( Germany, Spain, Italy, France, and United Kingdom) and Japan.
Request for a free sample report: https://www.delveinsight.com/sample-request/familial-adenomatous-polyposis-market
Familial Adenomatous Polyposis Disease Understanding and Treatment Algorithm
Individuals with FAP also have an increased chance of developing cancer in other organs, including the stomach, small intestine, and the pancreas and biliary tree. Risk for hepatoblastoma, a type of liver cancer, is increased in children with FAP. Desmoid tumors / desmoid fibromatosis, a locally aggressive tumor that does not spread (metastasize), and a type of brain tumor called medulloblastoma can also occur in some individuals. Risk for papillary thyroid cancer is also increased.
The DelveInsight Familial Adenomatous Polyposis market report gives a thorough understanding of the Familial Adenomatous Polyposis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
Some additional features of FAP may include:
· Osteomas (noncancerous bony growths, usually found on the jaw)
· Extra, missing, or unerupted teeth
· Congenital hypertrophy of the retinal pigment epithelium (CHRPE)
There are four subtypes of familial adenomatous polyposis:
· Classic familial adenomatous polyposis
· Attenuated familial adenomatous polyposis (AFAP)
· Gardner syndrome
· Turcot syndrome
Familial Adenomatous Polyposis Epidemiology
The Familial Adenomatous Polyposis epidemiology division provide insights about historical and current Familial Adenomatous Polyposis patient pool and forecasted trend for every seven major countries.
Key Findings
FAP has a birth incidence of about 1 per 8,300, manifests equally in both sexes, and accounts for less than 1% of colorectal cancer (CRC) cases. In the EU, prevalence is estimated at 1 in 11,300 to 1 in 37,600.
Familial Adenomatous Polyposis Emerging Therapy Assessment
· SLA Pharma: Eicosapentaenoic acid free fatty acid (EPA-FFA)
· Cancer Prevention Pharmaceuticals: Eflornithine (CPP-1X)
· Emtora Biosciences: eRapa
Click here and get access to a free sample copy of our report.
Familial Adenomatous Polyposis Market Outlook
Currently, the treatment paradigm for FAP includes surgical intervention such as Colectomy with ileorectal anastomosis (IRA), Restorative proctocolectomy with formation of ileoanal pouch (RPC) and Total proctocolectomy with ileoanal anastomosis (TPC).
However, various potential chemopreventive agents that are under studies include Nonsteroidal anti-inflammatory drugs (NSAIDs), ursodeoxycholic acid, statins, difluoromethylornithine (DFMO) and certain combinational therapies .
According to DelveInsight, Familial Adenomatous Polyposis market in 7MM is expected to change in the study period 2017–2030.
Related Reports
· Familial Mediterranean Fever — Pipeline Insight, 2021
· Familial Primary Pulmonary Hypertension Market Insights, Epidemiology, and Market Forecast-2030
· Familial Lipoprotein Lipase Deficiency — Pipeline Insights, 2021
· Familial Mediterranean Fever (FMF) — Market Insight, Epidemiology and Market Forecast — 2030
Visit our Insightful Press Release @https://icrowdnewswire.com/2021/05/03/rich-insights-into-end-stage-renal-disease-esrd-market-epidemiology-segmentation-pipeline-therapies-and-major-key-players-involved/
About DelveInsight:
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences providing comprehensive end-to-end solutions to improve performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
